B.S., Pharm.D., and Ph.D in Toxicology, University of Michigan
Diplomate, American Board of Toxicology
Dale E. Johnson (2014) Fast-tracking an orphan drug indication within a broader development project. Expert Opinion Orphan Drugs 2 (2) 107-111
Dana Felker, Alexandra Lynn, Sue Wang, Dale Johnson (2014) Evidence for a Potential Protective Effect of Carnitine-Pantothenic Acid Co-treatment on Valproic Acid-Induced Hepatotoxicity. Expert Rev Clin Pharmacol 7 (2) 211-218
Dale E Johnson (2013) Fusion of nonclinical and clinical data to predict human drug safety. Exp Rev Clin Pharmacol. 6(2) 185-195. Doi:10.1586/ecp.13.3
Dale E. Johnson and Grace L. Anderson (2013) Green Chemistry and Toxicology. Chapter 11 in "Green Chemistry and Engineering: A Pathway to Sustainability". Editors: M. Abraham and A.E. Marteel-Parrish. John Wiley & Sons, New York. Pp 325-353
Harmony Larson, Elena Chan, Sucha Sudarsanam, and Dale E. Johnson. (2012) Biomarkers. In Computational Toxicology Vol II. Chapter 11, Methods in Molecular Biology, Eds. Reisfeld B and Mayeno A.Humana Press, Springer Science, NY, NY. DOI 10.1007/978-1-62703-059-5_11
Dale E. Johnson and Sucha Sudarsanam (2012) Molecular challenges in frontloading toxicity testing of anti-cancer drugs in drug discovery. Encyclopedia of Drug Metabolism and Interactions. Chapter 3. Pp-1-20, Ed. Lyubinov AV, John Wiley & Sons, New York. DOI:10.1002/9780470921920.edm048
Dale E Johnson (2012) Estimating human cancer risk from rodent carcinogenicity studies: The changing paradigm for pharmaceuticals. J Drug Metab Toxicol. 3 (6) Open Access. http://dx.doi.org/10.4172/2157-7609.1000e114
Dale E. Johnson (2012) Predicting drug safety: Next generation solutions. J Drug Metab Toxicol 3 (2) Open Access http://dx.doi.org/10.4172/2157-7609.1000e106
Johnson Dale E, Srinivasan Subha, Bingham Jonathan, and Sudarsanam Sucha. (2012) Translational biology approach to identify causative factors for rare toxicities in humans and animals. Curr Drug Discov Technol 9(1) 77-80.
Dale E. Johnson (2010) Biotherapeutic first in human dose selection: making use of preclinical markers Expert Rev Clin Pharmacol 3(2) 231-242
Johnson DE, Smith DA, and Park BK (2010) Immunomodulatory Therapies and the risk of Opportunistic Infections Current Opinion Drug Disc Develop 13 (1) 20-22
Elena Chan, Marisela Tan, Jianni Xin, Sucha Sudarsanam, and Dale E. Johnson (2010) Interactions between Traditional Chinese Medicines and Western Therapeutics Current Opinion Drug Disc Develop 13(1) 58-73
Sucha Sudarsanam and Dale E. Johnson (2010) Functional consequences of mTOR inhibition Current Opinion Drug Disc Develop 13(1) 39-48
Johnson DE, Smith DA, and Park BK (2009) Pharmacogenomics and adverse drug reactions; prospective screening for risk identification. Current Opinion Drug Disc Develop 12(1) 27-30
Srinivasan S, Bingham J, and Johnson DE (2009) The ABC’s of Human Alternative Splicing: A Review of ATP-Binding Cassette Transporter Splicing. Current Opinion Drug Disc Develop 12(1) 149-158